Verition Fund Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-3,200
Closed -$281K 2854
2022
Q1
$281K Buy
+3,200
New +$277K ﹤0.01% 2186

Other funds holding NVS

Verition Fund Management's NVS Position: Q2 2026 in Review

Verition Fund Management increased its Novartis (NVS) stake by 250% in Q2 2026, buying an estimated $1.07M and bringing the position to 10,000 shares worth $1.57M. The position accounts for 0.01% of the portfolio, ranked #1220.

Verition Fund Management first reported a position in NVS in Q3 2015 and has held it in 14 quarters since. The position peaked at $2.96M in Q2 2018. 1,624 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Verition Fund Management held 10,000 shares of Novartis worth $1.57M as of Q2 2026.
  • Verition Fund Management bought 7,140 Novartis shares in Q2 2026, an estimated $1.07M.
  • Novartis made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1220 holding.
  • Verition Fund Management first reported a position in Novartis in Q3 2015 and has held it in 14 quarters since.
  • Verition Fund Management's Novartis position peaked at $2.96M in Q2 2018.
  • 1,624 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.